Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease

Livius Penter(Dana-Farber Cancer Institute), Catherine J. Wu(Dana-Farber Cancer Institute), Yang Liu(Dana-Farber Cancer Institute), Giacomo Oliveira(Dana-Farber Cancer Institute), Jerome Ritz(Dana-Farber Cancer Institute), Elizabeth A. Morgan(Brigham and Women's Hospital), Jacquelyn O. Wolff(Dana-Farber Cancer Institute), Rebecca Leonard(Dana-Farber Cancer Institute), Lin Yang(Second Affiliated Hospital of Jilin University), Aashna Jhaveri(Dana-Farber Cancer Institute), Pavan Bachireddy(The University of Texas MD Anderson Cancer Center), Jennifer Altreuter(Dana-Farber Cancer Institute), Manishkumar Patel(Icahn School of Medicine at Mount Sinai), Srinika Ranasinghe(Dana-Farber Cancer Institute), Taylor Robertson(Dana-Farber Cancer Institute), Helen X. Chen(National Cancer Institute), Seunghee Kim‐Schulze(Icahn School of Medicine at Mount Sinai), Len Taing(Dana-Farber Cancer Institute), Kenneth J. Livak(Broad Institute), Carrie Cibulskis, Scott J. Rodig(Brigham and Women's Hospital), Stacey Gabriel(Broad Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), Shuqiang Li(Anhui Normal University), Kathleen L. Pfaff(Dana-Farber Cancer Institute), Sacha Gnjatic(Tisch Hospital), Nicoletta Cieri(Broad Institute), F. Stephen Hodi(Harvard University), Jackson Southard(Dana-Farber Cancer Institute), Howard Streicher(National Cancer Institute), Franziska Michor(Dana-Farber Cancer Institute), Minkyung H. Song(National Cancer Institute), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Nicole M. Cullen(Dana-Farber Cancer Institute), Donna Neuberg(Otsuka (Japan))
Blood
January 27, 2023
Cited by 51


Related Papers